Gossamer Bio Shares Rise on FDA Update and Regained Rights to Seralutinib
Shares of Gossamer Bio (NASDAQ:GOSS) rose by 25% after the company announced a positive regulatory update regarding its lead drug candidate, seralutinib. The biotech firm completed a Pre-NDA Type B meeting with the FDA and received feedback supporting an NDA submission for PAH in September 2026. In addition to the FDA progress, Gossamer Bio regained full global rights to seralutinib from Chiesi following the termination of their collaboration. The deal included a $5 million one-time payment to Gossamer and allowed Chiesi to retain capped royalties on future sales and milestone payments. This move strengthens Gossamer's control over its key asset. Earlier in July, shareholders approved debt restructuring measures that reduced outstanding principal by about $115.9 million through an exchange of convertible notes. As of June 30, the company had approximately $57 million in cash and equivalents to support ongoing operations.
Tickers: $GOSS
Topics: biotech drug development licensing agreement nda filing